Preclinical PK/PD modeling and human efficacious dose projection for a glucokinase activator in the treatment of diabetes.
about
A comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo and in silico modeling techniques.Translational Modeling and Simulation in Supporting Early-Phase Clinical Development of New Drug: A Learn-Research-Confirm Process.Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape.An allometric pharmacokinetic/pharmacodynamics model for BI 893923, a novel IGF-1 receptor inhibitor.
P2860
Preclinical PK/PD modeling and human efficacious dose projection for a glucokinase activator in the treatment of diabetes.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Preclinical PK/PD modeling and ...... in the treatment of diabetes.
@en
Preclinical PK/PD modeling and ...... in the treatment of diabetes.
@nl
type
label
Preclinical PK/PD modeling and ...... in the treatment of diabetes.
@en
Preclinical PK/PD modeling and ...... in the treatment of diabetes.
@nl
prefLabel
Preclinical PK/PD modeling and ...... in the treatment of diabetes.
@en
Preclinical PK/PD modeling and ...... in the treatment of diabetes.
@nl
P2093
P2860
P1476
Preclinical PK/PD modeling and ...... in the treatment of diabetes.
@en
P2093
Bernadette Pascual
Kathleen M Ogilvie
Kirk Kozminski
Michael G Zager
Shaoxian Sun
P2860
P2888
P304
P356
10.1007/S10928-014-9351-7
P577
2014-02-28T00:00:00Z